

**CT Medical Assistance Program Prior Authorization (PA) Request Form****DUPIXENT (dupilumab)**

Prescriber Information	Patient Information
Prescriber's Name (Last, First):	Member's Name (Last, First):
Prescriber's NPI:	Member's ID:
Prescriber's Phone:	Patient's Date of Birth (MMDDCCYY):
Prescriber's Fax:	
Prescription Information	
Drug Requested:	Quantity Requested:

**Clinical Information**

<b>Eosinophilic Esophagitis (Patients 1+ years):</b> Is the patient 1 year of age or older, weigh at least 15 kg and have a diagnosis of eosinophilic esophagitis?	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Inadequately Controlled Moderate-to-Severe Atopic Dermatitis (Patients aged 6+ months):</b> Is the patient 6 months of age or older and have a diagnosis of moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapy or when those therapies are not advisable?	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Moderate-to-Severe Asthma (Patients 6+ years):</b> Is the patient 6 years of age or older and have a diagnosis of eosinophilic phenotype asthma (eg, peripheral blood eosinophils $\geq 150/\text{microL}$ ) or oral corticosteroid dependent asthma who continues to have disease complications despite receipt of standard-of-care therapy?	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyps (Patients 12+ years):</b> Is the patient 12 years of age or older and have a diagnosis of chronic rhinosinusitis with nasal polyps who continues to have disease complications despite receipt of standard-of-care therapy?	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Prurigo Nodularis (Patients 18+ years):</b> Is the patient 18 years of age or older and have a diagnosis of prurigo nodularis?	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Inadequately Controlled Chronic Obstructive Pulmonary Disease (Patients 18+ years):</b> Is the patient 18 years of age or older, have a diagnosis of chronic obstructive pulmonary disease and an eosinophilic phenotype who continues to have disease complications despite receipt of standard-of-care therapy?	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Chronic Spontaneous Urticaria (Patients 12+ years):</b> Is the patient 12 years of age or older, have a diagnosis of chronic spontaneous urticaria (CSU) and remain symptomatic despite H1 antihistamine treatment?	<input type="checkbox"/> Yes <input type="checkbox"/> No

**If you answered "No" to the question for the specific indication above, based on the client age or diagnosis, regarding the medication requested, please provide other information relating to the medical necessity (see Conn. Gen. Stat. § 17b-259b(a)) of this drug for this patient. Submit request, via email, to [rx.lmn@ct.gov](mailto:rx.lmn@ct.gov).**

Please Note: Pharmacies should not be contacting prescribers to provide pre-signed PA forms or submitting pre-signed forms for PA, nor should prescribing providers be requesting that pharmacies perform PA activities for them. PA requests must originate from the prescriber, and only the prescriber should sign the form at the time of PA submission. I certify that documentation is maintained in my files and the information given is true and accurate for the medication requested, subject to penalty under section 17b-99 of the Connecticut General Statutes and sections 17-83k-1- to 17-83k-7, inclusive, of the Regulations of Connecticut State Agencies. I certify that the above-referenced member is a patient under my clinic's/practice's ongoing care. Authorizations for Early Refill Requests are valid one time only.

**Signature of Prescriber\*** \_\_\_\_\_ **Date (MM/DD/CCYY)** \_\_\_\_\_ \*

Mandatory (others may not sign for prescriber). In accordance with federal law, prescribers must be enrolled in the Connecticut Medical Assistance Program (CMAP). CMAP will not pay for prescriptions written by a non-enrolled provider.

This form (and attachments) contains protected health information (PHI) for Gainwell Technologies and is covered by the Electronic Communications Privacy Act, 18 U.S.C. §2510-2521 and the Standards for Privacy of Individually Identifiable Health Information, 45 CFR Parts 160 and 164, which is intended only for the use of prior authorization. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited. Any unintended recipient should contact Gainwell Technologies by telephone at (860) 255-3900 or by e-mail immediately and destroy the original message.